These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 13827329)

  • 1. [On anti-myasthenic activity of an oxamide derivative (Win 8077)].
    GENTILI C; LOPERFIDO E
    Arch Ital Sci Farmacol; 1959 Oct; 9():517-28. PubMed ID: 13827329
    [No Abstract]   [Full Text] [Related]  

  • 2. WIN 8077 in treatment of myasthenia gravis; use of N,N'-bis (2-diethylaminoethyl) oxamide bis-2-chlorobenzyl chloride in fifty patients.
    SCHWAB RS; MARSHALL CK; TIMBERLAKE W
    J Am Med Assoc; 1955 Jun; 158(8):625-8. PubMed ID: 14381226
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical evaluation of ambenonium (mysuran) chloride.
    WESTERBERG MR
    AMA Arch Neurol Psychiatry; 1956 Jan; 75(1):91-4. PubMed ID: 13275166
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clinical trials with a new anti-myasthenic drug: N, N'-bis (2-diethylaminoethyl)-oxamide bis-2-chlorobenzyl chloride (Win 8077)].
    ALAJOUANINE T; CASTAIGNE P; BOURGUIGNON A; CAMBIER J
    Therapie; 1958; 13(5):799-804. PubMed ID: 13625192
    [No Abstract]   [Full Text] [Related]  

  • 5. In vitro activity of NN'-bis(diethylaminoethyl) oxamide bis benzyl-chloride (mytelase) on the cholinesterase of the electric organ of Electrophorus electricus, L.
    LEMME CC; SOLLERO L; HARGREAVES AB
    Arch Int Pharmacodyn Ther; 1959 Aug; 121():59-64. PubMed ID: 14415596
    [No Abstract]   [Full Text] [Related]  

  • 6. [Preliminary results with armin (ethyl-ethoxy phosphoryl p-nitrophenolate) in myasthenia gravis].
    VOJVODIC V; GRBESA B; STEVANOVIC M; BINENFELD Z; GAZIVODA N; BARYLA K; BOZIC V
    Vojnosanit Pregl; 1960 Nov; 17():1167-70. PubMed ID: 13781940
    [No Abstract]   [Full Text] [Related]  

  • 7. [Therapeutic value of new antimyasthenia drugs according to clinical and electromyographic aspects].
    EMERYK B; BIEZANSKI W
    Neurol Neurochir Psychiatr Pol; 1959; 9():471-83. PubMed ID: 13820172
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacokinetic studies of ambenonium chloride in patients with myasthenia gravis.
    Tharasse-Bloch C; Chabenat C; Boucly P; Marchand J; Elkharrat D; Boucly-Goester C; Gajdos P
    Eur J Drug Metab Pharmacokinet; 1991; 16(4):299-303. PubMed ID: 1823874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postoperative (adynamic) ileus; its prevention by ambenonium chloride.
    BILBAO C; CANO M; MONTEAVARO LOMBARD F; PARDO G; GASSO D
    Surgery; 1959 Dec; 46():1043-6. PubMed ID: 13800669
    [No Abstract]   [Full Text] [Related]  

  • 10. WIN 8077 in the treatment of sixty myasthenia gravis patients; a twelve-month report.
    SCHWAB RS
    Am J Med; 1955 Nov; 19(5):734-6. PubMed ID: 13268473
    [No Abstract]   [Full Text] [Related]  

  • 11. [Pregnancy and normal birth in a myasthenic subject treated with anticholinesterase drugs].
    VAGUE J; CHOSSON J; MOUREN P; CODACCIONI JL; AYME Y
    Mars Med; 1962; 99():556-61. PubMed ID: 13924148
    [No Abstract]   [Full Text] [Related]  

  • 12. [Therapy of pseudoparalytic myasthenia gravis].
    Fasshauer K
    Dtsch Med Wochenschr; 1975 Oct; 100(44):2283-4. PubMed ID: 1183327
    [No Abstract]   [Full Text] [Related]  

  • 13. [Further progress in therapy of myasthenic syndrome].
    STRUPPLER A
    Med Monatsschr; 1953 Jul; 7(7):428-32. PubMed ID: 13098853
    [No Abstract]   [Full Text] [Related]  

  • 14. [Current therapy of myasthenia gravis. I. Specific symptomatic therapy].
    Erbslöh F
    Nervenarzt; 1972 Jul; 43(7):341-4. PubMed ID: 4627866
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of 3-hydroxy phenyl-dimethylethylammonium chloride (tensilon) in myasthenia gravis.
    WESTERBERG MR; MAGEE KR; SHIDEMAN FE
    Med Bull (Ann Arbor); 1951 Sep; 17(9):311-6. PubMed ID: 14893613
    [No Abstract]   [Full Text] [Related]  

  • 16. [Ambenonium chloride. Study of its use for 3 years in cases of postoperative abdominal distension and urinary retention].
    BILBAO C; CANO M; MONTEAVARO LOMBARD F; PARDO GOMEZ G; GASSO MIGUEL D
    Rev Fac Cienc Med Cordoba; 1959; 17():269-75. PubMed ID: 13800670
    [No Abstract]   [Full Text] [Related]  

  • 17. [Myasthenia and mediastinal tumor; favorable effect of a new anti-myasthenic preparation].
    SUTTER JM; LARMANDE AM
    Rev Otoneuroophtalmol; 1953; 25(4):231-4. PubMed ID: 13112901
    [No Abstract]   [Full Text] [Related]  

  • 18. [Current trends in medical and surgical treatment of myasthenia gravis with persistence of the thymus and long-term results of some operated cases].
    Sunseri S; Sottosanti M; Spinelli P
    Arch Chir Torac Cardiovasc; 1970; 26(1):19-34. PubMed ID: 5477673
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of myasthenia gravis].
    Szobor A; Klein M
    Psychiatr Neurol Med Psychol (Leipz); 1976 Jan; 28(1):33-42. PubMed ID: 940881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [First therapeutic results with mytelase (mysuran, win 8077) in myasthenia].
    DESMEDT JE
    Acta Neurol Psychiatr Belg; 1957 Feb; 57(2):94-103. PubMed ID: 13424193
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.